Abstract
The overall prevalence of hepatitis C (HCV) among injection drug users (IDUs) in the United States is estimated at about 53%. Harm-reduction strategies like syringe service programs (SSP) and medications for opioid use disorder (MOUD) are effective in reducing HCV acquisition risk, and a combination of both provides an additive effect. This research aims to evaluate the cost-effectiveness of SSP alone, MOUD alone, and SSP+MOUD combination in preventing HCV cases among opioid IDUs in the United States.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call